BOSTON SCIENTIFIC CORPORATION

BSX
Exchange NYQ, Currency in USD
Loading price...

Overview

Previous Close57.64
Open53.13
Ask50.29
Bid50.27
Day's Range50.04 - 53.17
52 Week Range50.04 - 109.50
PE Ratio(TTM)21.10
Market Cap74.94B
Volume38.87M
Avg. Volume16.51M
12 Months Earnings3.56B
12 Months Revenue20.61B

Performance

ABSCAGR
YTD1 Month3 Months1 Year2 Years5 Years10 Years
No results to display

Profit/Loss

PARTICULARSTTM20252025202420232022
Operating Revenue20.61B20.07B18.49B16.75B14.24B12.68B
Cost of Revenue6.36B6.22B5.87B5.26B4.34B3.96B
Gross Profit14.26B13.85B12.63B11.49B9.89B8.73B
Operating Expenses10.15B9.88B9.24B8.49B7.48B6.69B
Profit after Tax (Net Income)3.56B2.90B2.51B1.85B1.59B698.00M

Company Profile

Sector: Healthcare
Industry: Medical Devices
HQ Location: Marlborough, United States
Website: https://www.bostonscientific.com
Chairman, President & CEO: Mr. Michael F. Mahoney
Employees: 59,000
About Company:
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
DISCLAIMER: Stock prices are not real time and the delay can range from a few seconds to several minutes. The data displayed are solely for informational purposes, not for trading purposes or advice.